Michael Moore and Fritz Frickel join MISSION board
This article was originally published in Scrip
Executive Summary
MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating enzyme family for the treatment of cancer, has appointed Dr Michael Moore executive chair and Dr Fritz Frickel non-executive director. Dr Moore has more than two decades of senior management experience in the biotech sector, most recently as CEO of Piramed. He is currently a non-executive director of several companies including PsiOxus Therapeutics. Dr Frickel is currently an independent advisor to venture capital firms, biotech start-ups and universities, having previously served as senior vice-president of R&D and acting CEO of Alantos.